Serina Therapeutics, Inc.
SER•NYSEAMERICAN•Healthcare•Biotechnology

About Serina Therapeutics

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOSteven Ledger
Founded2017
IPO DateNovember 29, 2018
Employees13
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNYSEAMERICAN (NYSEAMERICAN)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websiteserinatherapeutics.com
Phone256 327 9630
Address
601 Genome Way, Suite 2001 Huntsville, Alabama 35806 United States

Corporate Identifiers

CIK0001708599
CUSIP81751A108
ISINUS81751A1088
EIN82-1436829
SIC2834

Leadership Team & Key Executives

Steven A. Ledger
Chief Executive Officer and Director
Dr. Balkrishan Gill Ph.D.
Executive Chairman
Dr. J. Milton Harris Ph.D.
Co-Founder, Director Emeritus and Chair of Scientific Advisory Board
Gregory S. Curhan
Chief Financial Officer
Dr. Srini Tenjarla
Senior Vice President of Chemistry, Manufacturing and Controls and Formulation
Dr. Randall W. Moreadith M.D., Ph.D.
Chief Development Officer
Dr. Joshua Thomas Ph.D.
Head of Chemistry